Editorial

Is This Medicine REALLY Involved in a Drug Interaction?

Authors: Steven Joseph Haas, B Pharm, B Pharm Sci (Hons), MSHPA, MAEA

Abstract

In today’s advanced medical profession, there is an ever increasing amount of evidence developing in relation to a myriad of drug-drug interactions,1,2 a trend which is set to continue with an aging population and further development of pharmaceutical technologies in the future. This begs to question as to whether it is safe to presume that a specific drug-drug interaction does not exist if it has not been identified and published. With an exponentially expanding number of drug combinations at our disposal for the treatment of various conditions upsetting our patients, all clinicians must remain vigilant to the possibility of an unknown situation affecting the patient under their care, in the interests of the patient’s safety and well being. Our aim must always remain to provide the correct drug, at the correct dose, at the correct time, to the correct patient (and hopefully the correct number of medications to ensure compliance and avoid confusion by patients and clinicians alike!). Obviously, this is not always an easy task to accomplish considering the demands of the health profession and the continual need to remain informed and updated.

This content is limited to qualifying members.

Existing members, please login first.

If you have an existing account please login now to access this article or view your purchase options.

Purchase only this article ($15)

Create a free account, then purchase this article to download or access it online for 24 hours.

Purchase an SMJ online subscription ($75)

Create a free account, then purchase a subscription to get complete access to all articles for a full year.

Purchase a membership plan (fees vary)

Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.

References

1. Bjerrum L, Andersen M, Petersen G, et al. Exposure to potential drug interactions in primary health care. Scand J Prim Health Care 2003;21:153–158.
 
2. Maas R, Boger RH. Antihypertensive therapy: special focus on drug interactions. Expert Opin Drug Saf 2003;2:549–579.
 
3. Kiley CA, Cragin DJ, Roth BJ, et al. Omeprazole-associated digoxin toxicity South Med J 2007;100:400–402.
 
4. Kramer MS, Leventhal JM, Hutchinson TA, et al. An algorithm for the operational assessment of adverse drug reactions. I. Background, description, and instructions for use. JAMA 1979;242:623–632.
 
5. Bauman JL, Didomenico RJ, Galanter WL. Mechanisms, manifestations, and management of digoxin toxicity in the modern era. Am J Cardiovasc Drugs 2006;6:77–86.
 
6. Dec GW. Digoxin remains useful in the management of chronic heart failure. Med Clin North Am 2003;87:317–337.
 
7. Smalley W, Shatin D, Wysowski DK, et al. Contraindicated use of cisapride: impact of food and drug administration regulatory action. JAMA 2000;284:3036–3039.
 
8. Wysowski DK, Bacsanyi J. Cisapride and fatal arrhythmia. N Engl J Med 1996;335:290–291.
 
9. Aronson JK. Unity from diversity: the evidential use of anecdotal reports of adverse drug reactions and interactions. J Eval Clin Pract 2005;11:195–208.
 
10. Kelly WN. The quality of published adverse drug event reports. Ann Pharmacother 2003;37:1774–1778.